General Biotechnology

General Biotechnology

Canadian Venture Capital – Unlocking the Funding Challenge

Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercial potential. A significant problem has been a lack of sufficient venture capital to take early-stage companies to the next level. Several recent developments may signal the arrival of a more positive venture-funding environment for life sciences and health technology enterprises, including the development of the Canadian government’s C$400 million Venture Capital Action Plan; pharmaceutical companies electing to establish or investing in venture funds and providing strategic support to early-stage ventures, including through the creation of research centres; and recent successful liquidity events for venture investors.

Canadian Venture Capital – Unlocking the Funding Challenge Read Post »

General Biotechnology

Deciding between biobetter versus biosimilar development options based on net present value calculations

 

Abstract

The growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster biologics are approaching their patent expiries. Companies need to make decisions whether to invest in biosimilars or in biobetters with enhanced properties, the latter enabling favorable differentiation vis-à-vis the original product on the one hand and biosimilars on the other hand. Net present value (NPV) modelling was applied to evaluate the financial attractiveness of two categories of biobetters in comparison to biosimilars, and recommendations are made which options should be preferred depending on a company’s business model.

Deciding between biobetter versus biosimilar development options based on net present value calculations Read Post »

General Biotechnology

A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
Go to paperABSTRACT: Patent analytical da…

A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape Read Post »

Biotechblog
Scroll to Top